This prospective randomized double-blinded controlled study will be conducted to evaluate the effect of adding calcitonin to bupivacaine in thoracic paravertebral block for patients undergoing thoracotomy.

开始日期2024-03-28

申办/合作机构

Tanta University

IRCT20220523054971N1 / Recruiting临床3期IIT

Evaluation of response to calcitonin treatment in patients with frozen shoulder in selected hospitals of Islamic Azad University of Medical Sciences, Tehran in 2022

开始日期2021-12-19

申办/合作机构

Islamic Azad University

100 项与鲑降钙素相关的临床结果

登录后查看更多信息

100 项与鲑降钙素相关的转化医学

登录后查看更多信息

100 项与鲑降钙素相关的专利（医药）

登录后查看更多信息

1,237

项与鲑降钙素相关的文献（医药）

2024-10-01·Peptides

Modulation of amylin and calcitonin receptor activation by hybrid peptides

Article

作者: Lee, Sangmin

Calcitonin peptide hormone controls calcium homeostasis by activating the calcitonin receptor. When the calcitonin receptor forms a complex with an accessory protein, the complex functions as the receptors for another peptide hormone amylin. The amylin receptors are the drug target for diabetes and obesity treatment. Since human amylin can produce aggregates, rat amylin that does not form aggregates has been commonly used for research. Interestingly, calcitonin originated from salmons was reported to interact with human amylin receptors with higher affinity/potency than endogenous rat amylin. Here, the peptide hybrid was made of a rat amylin N-terminal fragment and a salmon calcitonin C-terminal fragment. This novel hybrid peptide showed higher potency for human amylin receptor 1/2 activation by 6- to 8-fold than endogenous rat amylin. To further examine the role of the peptide C-terminal fragment in receptor activation, another hybrid peptide was made where salmon calcitonin N-terminal 21 amino acids were fused with rat amylin C-terminal 11 amino acids. The rat amylin C-terminal fragment was previously reported to have relatively low affinity for calcitonin receptor extracellular domain. As expected, this calcitonin-amylin hybrid peptide decreased the potency for calcitonin receptor activation by 3-fold compared to salmon calcitonin. The hybrid strategy used in this study significantly changed the peptide potency for amylin and calcitonin receptor activation. These results provide insight into the role of peptide C-terminal fragments in modulating amylin and calcitonin receptor activation.

2024-10-01·Cancer Reports

Unusual Presentation of Metastatic Medullary Thyroid Cancer Involving Bone Marrow, Kidneys, and Adrenal Gland: A Literature Review Based on a Case Report

Review

作者: Taheri, Homa ; Payab, Moloud ; Alipour, Neda ; Ebrahimi, Pouya ; Shariati, Alireza ; Ebrahimpur, Mahbube ; Nozheh, Aysan ; Tavangar, Seyed Mohammad

ABSTRACTBackgroundMedullary thyroid cancer (MTC) is one of the rare neuroendocrine malignancies. This cancer is hereditary in approximately 20% of cases. Although lymph node (LN) metastasis is prevalent in MTC, distant metastasis is not commonly seen in these patients. The most common locations for metastasis are the lungs, liver, and bones. This study presents an extremely rare MTC metastasis to bone marrow (BM) and adrenal gland, which has not been reported before.CaseThe patient was a 50‐year‐old man with a diagnosis of MTC and total thyroidectomy 2 months before his presentation. He came to the emergency department (ED) complaining of dyspnea, diffuse bone pain, nonbloody diarrhea, and abdominal cramps starting in the last month before. Initial treatment with intravenous fluid infusion and loperamide, due to the provisional diagnosis of infectious diarrhea, was ineffective. Further assessments revealed severe pancytopenia and a massive tumor above the left kidney. Bone marrow aspiration (BMA) and biopsy (BMB) led to the diagnosis of invasive metastasis of the MTC to the BM and the left adrenal gland. In the initial evaluations, his COVID‐19 test became positive, and despite all efforts, his condition deteriorated, and he died 5 days after admission due to respiratory distress.ConclusionMost MTC cases present with thyroid nodules in the initial steps and are confined to the thyroid gland or the adjacent LNs. These cases are mostly cured by thyroidectomy and LN dissection. This neuroendocrine cancer infrequently becomes aggressive and involves other parts of the body. However, involving BM or adrenal gland has been scarcely reported. Due to ineffective red and white blood cell production, BM metastasis can cause pancytopenia and, consequently, pallor, fatigue, dyspnea, and susceptibility to infections. High calcitonin levels can also cause diarrhea. The initial diagnosis is mostly with neck ultrasound (US) and fine needle aspiration (FNA). Total thyroidectomy is the main therapeutic option for these patients. Calcitonin and carcinoembryonic antigen (CEA) are sensitive indicators of recurrence or remaining tumors, which might be helpful for the initial diagnosis and postoperation follow‐up. Although extremely rare, invasive metastasis of MTC might involve unusual body organs such as the BM or adrenal glands. In cases of unjustifiable pancytopenia or adrenal dysfunction in MTC‐positive patients, these possibilities should be considered and ruled out by some specific evaluations, such as bone marrow biopsy and contrast‐enhanced imaging.

2024-10-01·Journal of Endocrinology

Thyroglobulin and calcitonin measurements: pitfalls and future perspectives

Review

作者: Heijboer, Annemieke C. ; Mater, Amber ; Hillebrand, Jacquelien J ; Boelen, Anita

Thyroid cancer is the most prevalent endocrine cancer. Prognosis depends on type and stage of cancer when discovered. Treatment involves (hemi-)thyroidectomy, possibly followed by additional therapeutic options. After treatment, patients are monitored using serum concentrations of endocrine tumour marker thyroglobulin in case of differentiated cancer and calcitonin in case of medullary thyroid cancer. Measuring thyroglobulin and calcitonin concentrations in serum may be challenging. In this review we give a complete overview of the evolvement in laboratory measurements regarding thyroglobulin and calcitonin with an emphasis on (pre-)analytical challenges and potential approaches to overcome current pitfalls.

项与鲑降钙素相关的新闻（医药）

2024-10-22

·Endpoints

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

In its quest to stay at the top of the obesity drug market, Eli Lilly is following in Novo Nordisk’s footsteps by pursuing a new class of weight loss drugs. The Indianapolis drug giant said this month it is paying up to $1.4 billion to KeyBioscience to again try to develop dual amylin and calcitonin receptor agonists, or DACRAs, which aim to reduce body weight, control glucose levels and improve insulin action. It’s been seven years in the making. Lilly originally teamed up with the Swiss biotech in 2017 , with plans to develop DACRAs for diabetes and nonalcoholic steatohepatitis. The companies eventually slashed three daily compounds in favor of a once-weekly option, according to Morten Karsdal, CEO of KeyBioscience’s parent company Nordic Bioscience. DACRAs are now shedding its niche status amid the soaring popularity of GLP-1s like Lilly’s weight management drug Zepbound and the hunt for better obesity drugs. Ten years from now, Stifel bankers predict DACRAs, amylin agonists and GIP antagonists could be “good options” for patients who “can’t tolerate GLP-1s.” Novo Nordisk is the furthest along with CagriSema, a combination of its megablockbuster semaglutide — known as Wegovy for weight loss — and an amylin agonist asset known as cagrilintide. It’s expected to have Phase 3 data by the end of the year. Other companies are prepping for the clinic, including Viking Therapeutics and Metsera , which announced a manufacturing deal earlier this month to shore up development capabilities well in advance of commercialization. AstraZeneca , Zealand Pharma and Gubra are also working in the broader amylin class. “As we’re looking for ways to go beyond what a GLP-1 mono-agonist or what a dual-agonist can do in terms of maximum weight loss, adding amylin is probably the next priority in your order of operations for mechanisms you’d want to look at,” Metsera CEO Whit Bernard told Endpoints News . Bernard said Metsera will “soon” enter the clinic with its experimental therapy, a combination of a DACRA, dubbed MET-233, and a GLP-1 injectable, MET-097, which had encouraging early-stage data last month. Executive chair Clive Meanwell previously told Endpoints the combo would be “very competitive” if it induces weight loss of 25% to 30%. Beyond weight loss, Karsdal makes the pitch that DACRAs have additional benefits. “This mode of action should be protecting bone and muscle and other organs,” he said, “so there’s clearly a space for this in the future.” KeyBioscience has been on a winding journey. Its parent company is Danish biomarker and lab services company Nordic Bioscience, which partnered with peptide biotech Unigene Laboratories in 2011 to form a joint venture to create new medicines. Unigene went bankrupt in mid-2013, and Nordic bought out its stake. By 2017, it received $55 million upfront and an undisclosed amount of biobucks as part of a deal with Lilly. But all three assets in that tie-up, including a Phase 2 diabetes drug, wound up on the shelf. Again, KeyBioscience was at a crossroads. “We actually decided with Lilly to terminate those because we wanted to focus on weekly formulations,” Karsdal said, though he declined to detail what led the partners to switch to the once-weekly route after having gone into clinical trials. “I unfortunately cannot comment publicly because the amylin receptor and calcitonin receptor biology is a hot topic for many, and there are some tricks that I cannot disclose,” Karsdal said. KeyBioscience’s once-weekly DACRA known as KBP-336 is now set to enter a global Phase 2 trial investigating the injectable’s ability to reduce weight and tame osteoarthritis pain in people with obesity by the end of the year. KeyBioscience will run the trial, and Lilly has the rights to continue developing it after that, Karsdal said. The trial may include patients who are already on GLP-1s, he said. KBP-336, which is derived from salmon calcitonin , could have broad utility. The calcitonin hormone helps keep bones healthy and can help thwart pain, lending confidence to KeyBioscience’s plans to also test it in osteoarthritis . “We’ve actually been in two Phase 3 studies before with an oral formulation of salmon calcitonin that had an effect on pain in one of the studies, so we’re reasonably convinced that we will get a superior effect on pain,” Karsdal said.

临床2期并购

2024-06-24

·信狐药迅

仿制药申请12个品规、进口上市4个品规发通知件；临床申请品种均默示许可| 新获批（6.17-6.23）

每周药品注册获批数据，分门别类呈现，一目了然。(6.17-6.23）新药上市申请药品名称企业注册分类受理号TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200026国;CXHS2200026TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200025国;CXHS2200025TQ-B3139胶囊正大天晴药业集团南京顺欣制药有限公司1CXHS2200024国;CXHS2200024甲磺酸奥瑞替尼片南京圣和药业股份有限公司1CXHS2101058国;CXHS2101058 新药临床申请药品名称企业注册分类受理号HRS-9813片广东恒瑞医药有限公司1CXHL2400397HRS-9813片广东恒瑞医药有限公司1CXHL2400396PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400372PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400371WD-890片浙江文达医药科技有限公司1CXHL2400361WD-890片浙江文达医药科技有限公司1CXHL2400360WD-890片浙江文达医药科技有限公司1CXHL2400359WD-890片浙江文达医药科技有限公司1CXHL2400358ZX-8177片南京征祥医药有限公司1CXHL2400347ZX-8177片南京征祥医药有限公司1CXHL2400346西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400342西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400341RS-C1001片青岛睿森生物科技有限公司1CXHL2400340RS-C1001片青岛睿森生物科技有限公司1CXHL2400339PH009-1片苏州浦合医药科技有限公司1CXHL2400336PH009-1片苏州浦合医药科技有限公司1CXHL2400335CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400334CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400333CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400332CS060304片凯思凯迪(上海)医药科技有限公司1CXHL2400331HRS-7249注射液上海拓界生物医药科技有限公司1CXHL2400329BC-007默化(无锡)生物科技有限公司1CXHL2400326GFH375片劲方医药科技(上海)有限公司1CXHL2400328GFH375片劲方医药科技(上海)有限公司1CXHL2400327注射用WP1302百明信康生物技术(浙江)有限公司1CXHL2400318洛索洛芬钠凝胶贴膏海南赛立克药业有限公司4CYHL2400073注射用BL-M17D1成都百利多特生物药业有限责任公司1CXSL2400237重组抗HER3人源化单抗注射液上海生物制品研究所有限责任公司1CXSL2400232注射用LM-2417礼新医药科技(上海)有限公司1CXSL2400223AK129注射液康方汇科(上海)生物有限公司1CXSL2400220CM355北京天诺健成医药科技有限公司1CXSL2400217IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400219IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400216注射用SKB518四川科伦博泰生物医药股份有限公司1CXSL2400215注射用MK-2870默沙东研发(中国)有限公司1CXSL2400214司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400241司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400240LPS-001注射液乐普药业股份有限公司3.3CXSL2400231QL2108注射液齐鲁制药有限公司3.3CXSL2400221泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2400213 仿制药申请药品名称企业注册分类受理号盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301346盐酸异丙肾上腺素注射液成都欣捷高新技术开发股份有限公司3CYHS2301345甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300705甲硫酸新斯的明注射液陕西丽彩药业有限公司3CYHS2300704美索巴莫注射液南京赛瑞谱顿制药有限公司3CYHS2300368盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201943国;CYHS2201943盐酸非索非那定干混悬剂济川药业集团有限公司3CYHS2201942国;CYHS2201942盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201844国;CYHS2201844盐酸氨溴索滴剂丽彩甘肃西峰制药有限公司3CYHS2201843国;CYHS2201843盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201800国;CYHS2201800盐酸左沙丁胺醇雾化吸入溶液宏越科技(湖州)有限公司3CYHS2201799国;CYHS2201799己酮可可碱注射液江西和盈药业有限公司3CYHS2201773国;CYHS2201773铝碳酸镁混悬液杭州民生健康药业股份有限公司3CYHS2201508国;CYHS2201508利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201485国;CYHS2201485利伐沙班细粒剂浙江恒研医药科技有限公司3CYHS2201484国;CYHS2201484人纤维蛋白原广东双林生物制药有限公司3.4CXSS2300008醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303412醋酸阿托西班注射液湖南科伦制药有限公司4CYHS2303411氟比洛芬凝胶贴膏河北鼎泰制药有限公司4CYHS2302482氢溴酸伏硫西汀片石家庄龙泽制药股份有限公司4CYHS2302355磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302241磷酸奥司他韦胶囊安徽省先锋制药有限公司4CYHS2302239注射用甲泼尼龙琥珀酸钠海南倍特药业有限公司4CYHS2302171鲑降钙素注射液海南紫程众投生物科技有限公司4CYHS2302116罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302031罗库溴铵注射液陕西金思铭生物技术有限公司4CYHS2302030黄体酮阴道缓释凝胶浙江爱生药业有限公司4CYHS2301662硫酸氨基葡萄糖胶囊山东朗诺制药有限公司4CYHS2300975硫酸氨基葡萄糖胶囊药大制药有限公司4CYHS2300757乳酸环丙沙星氯化钠注射液江苏长江药业有限公司4CYHS2300644盐酸艾司洛尔氯化钠注射液石家庄四药有限公司4CYHS2300581左卡尼汀口服溶液浙江北生药业汉生制药有限公司4CYHS2300528麦考酚钠肠溶片四川科伦药业股份有限公司4CYHS2300453复方电解质注射液广东科伦药业有限公司4CYHS2300379复方电解质注射液广东科伦药业有限公司4CYHS2300378尼莫地平注射液四川汇宇制药股份有限公司4CYHS2300281布南色林片合肥英太制药有限公司4CYHS2300237富马酸喹硫平缓释片山东京卫制药有限公司4CYHS2300181左西孟旦注射液海南倍特药业有限公司4CYHS2300170精氨酸布洛芬颗粒海南葫芦娃药业集团股份有限公司4CYHS2300159氯苯唑酸葡胺软胶囊齐鲁制药有限公司4CYHS2300076尼莫地平注射液北京柏雅联合药物研究所有限公司4CYHS2300056利托那韦片海南先声药业有限公司4CYHS2300046骨化三醇注射液成都国为生物医药有限公司4CYHS2201941国;CYHS2201941他达拉非片河南比福制药股份有限公司4CYHS2201830国;CYHS2201830磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201767国;CYHS2201767磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201766国;CYHS2201766磷酸奥司他韦胶囊山东新时代药业有限公司4CYHS2201765国;CYHS2201765罗库溴铵注射液江苏正大清江制药有限公司4CYHS2201743国;CYHS2201743甲泼尼龙片辰欣药业股份有限公司4CYHS2201704国;CYHS2201704贝前列素钠片重庆药友制药有限责任公司4CYHS2201706国;CYHS2201706孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201672国;CYHS2201672孟鲁司特钠咀嚼片海南葫芦娃药业集团股份有限公司4CYHS2201671国;CYHS2201671注射用氯诺昔康广州曼翔医药有限公司4CYHS2201418国;CYHS2201418普瑞巴林胶囊江苏恩华药业股份有限公司4CYHS2201265国;CYHS2201265结构脂肪乳注射液(C6-24)四川国瑞药业有限责任公司4CYHS2201238国;CYHS2201238富马酸丙酚替诺福韦片温岭市创新生物医药科技股份有限公司4CYHS2200916国;CYHS2200916醋酸奥曲肽注射液四川汇宇制药股份有限公司4CYHS2200889国;CYHS2200889普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200880国;CYHS2200880普瑞巴林胶囊山东新华制药股份有限公司4CYHS2200879国;CYHS2200879富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200735国;CYHS2200735富马酸伏诺拉生片宜昌人福药业有限责任公司4CYHS2200734国;CYHS2200734磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200560国;CYHS2200560磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200559国;CYHS2200559磷酸西格列汀片苏州天马医药集团天吉生物制药有限公司4CYHS2200558国;CYHS2200558左乙拉西坦口服溶液湖南嘉恒制药有限公司4CYHS2200388国;CYHS2200388 进口申请药品名称企业注册分类受理号磷酸芦可替尼片Novartis Pharma Schweiz AG5.1JXHS2300054盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300024盐酸卡马替尼片Novartis Pharma Schweiz AG5.1JXHS2300023亚甲蓝肠溶缓释片Alfasigma S.p.A.5.1JXHS2300021爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200031国;JXHS2200031爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200030国;JXHS2200030爱塔乐伦颗粒口服干混悬剂PTC Therapeutics International Limited5.1JXHS2200029国;JXHS2200029地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200036国;JYHS2200036地拉罗司颗粒MSN Laboratories Private Limited5.2JYHS2200035国;JYHS2200035注射用多黏菌素E甲磺酸钠Xellia Pharmaceuticals ApS5.2JYHS2101061国;JYHS2101061利奈唑胺葡萄糖注射液北京费森尤斯卡比医药有限公司5.2JYHS2000050国;JYHS2000050BAY 2862789口服溶液Bayer AG1JXHL2400081Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400080Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400079Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400078Bomedemstat胶囊Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2400077Capivasertib片AstraZeneca AB2.4JXHL2400087Capivasertib片AstraZeneca AB2.4JXHL2400086VAY736注射液Novartis Pharma AG1JXSL2400070BAY 3018250Bayer AG1JXSL2400068帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400074Ravulizumab注射液Alexion Pharmaceuticals Inc.3.1JXSL2400075 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

申请上市

2024-03-04

·赛柏蓝

斥资4.5亿收购，呼吸用药市场生变

作者 | 陈芋来源 | 赛柏蓝 014.58亿元现金收购60%股份赛托生物拿下呼吸领域1类创新药近日，甾体药物原料药龙头企业赛托生物发布公告称，拟通过支付现金4.58亿元的方式收购银谷制药60%股份。本次收购完成后，银谷制药将纳入赛托生物合并报表范围内，预计将在合并资产负债表中将增加商誉约3.05亿元，商誉占赛托生物最近一期经审计净资产的15.03%。赛托生物是国内首家规模化采用合成生物法制取甾体药物原料的生产商，自2019年启动“中间体-原料药-制剂”全产业链升级战略以来，积极拓展高端中间体产品，同时利用自身处于产业链上游的优势，向下游呼吸类高端特色原料药和制剂领域进行升级。赛托生物表示，甾体激素类药物众多，在呼吸科的使用是重要应用场景之一，银谷制药在呼吸科药品领域拥有1类创新药及吸入制剂开发经验，契合赛托生物战略规划与发展方向。银谷制药成立于2007年，以化药研发为核心，集新药研发、原料合成、制剂生产和药品销售为一体，主要专注于过敏性鼻炎和急慢性呼吸道疾病、骨质疏松等疾病治疗领域，现有业务主要为甾体激素类药物中间体及原料药的生产销售，拥有喷鼻剂、气雾剂、小容量注射剂、片剂、胶囊、颗粒剂等多剂型生产线。据悉，银谷制药主要产品包括我国首个高选择性抗胆碱能受体拮抗剂1类新药苯环喹溴铵鼻喷雾剂（商品名：必立汀）；国内首仿鲑降钙素注射液（商品名：固泰宁）、鲑降钙素鼻喷雾剂（商品名：金尔力）；以及吸入用盐酸氨溴索溶液（商品名：力希畅）。其苯环喹溴铵鼻喷雾剂适应症包括变应性鼻炎，可拓展至哮喘及慢性阻塞性肺疾病，已被纳入多份治疗指南，2022年纳入《国家医保目录》。银谷制药对全国30个省（自治区/直辖市）的省会及重点城市的高等级医疗终端以及二级以下城市、县乡医疗机构及社区基层卫生机构有所覆盖，产品覆盖医疗机构终端总数超过2000 家、零售终端门店超过2万家。02原料、制剂、能源…持续收并购，纵向布局全产业链 2023年，银谷制药营业收入为2.15亿元，同比增长21.16%；由于销售收入增长销售毛利润同步增长，净利润同比扭亏为盈，达到1395.7万元，与上年度的-133.96万元相比，同比增长1141.89%。据收购公告，2024年1月，银谷制药实现销售收入3619.28万元（未经审计），同比大幅增长，占2024年度业绩预测收入的12.63%。另外，其已经签署订单和正在签署订单的合同金额已达3.19亿元（含税），上述订单分批次按需发货，年度合同确认销售金额预计能够覆盖2024年度预测收入。整体来看，银谷制药盈利预期较强，但赛托生物也表示，银谷制药存在因所在行业不景气或自身因素导致其未来经营状况未达预期风险及商誉减值风险。自2017年上市至此次收购银谷制药，赛托生物已进行了五次外延式并购，涉及植物甾醇企业迪森生物、蒸汽能源企业润鑫热力、意大利药企Lisapharma、和诺倍康药业等，覆盖原料、制剂，甚至能源领域。 2015年，原山东省环境保护厅等部门联合下发文件对燃煤锅炉超低排放改造提出严格要求，彼时的赛托生物业务规模正不断扩大，若继续以原有设备继续经营则存在环保风险。 2018年，赛托生物以1.15亿元收购菏泽润鑫热力有限公司100%股权，其供应的蒸汽能源为赛托生物提供了更为稳定的保障，同时有利于维持企业独立性，减少了关联交易。 2019年，赛托生物又收购了意大利Lisapharma，据悉，Lisapharma主营药品、化妆品和营养品的生产与销售及其相关辅助活动，其抗生素、解毒剂、抗炎皮质类固醇等，已获得了意大利药物生产许可、意大利销售许可、欧盟GMP证书资质。此次收购，赛托生物一方面能从海外引进高端原料药品种，并基于此实现高附加值生产；另一方面，也可借Lisapharma在欧洲的设施、资质、长期生产经营经验以及本地化优势，开拓海外市场，使赛托生物新药在国内外同时文号申报成为可能，进一步拓展其产业链。目前，Lisapharma作为赛托生物的海外子公司拥有鲑降钙素注射液、阿曲库铵注射液、硫糖铝软膏等20余款制剂产品，已经完成鲑降钙素和曲安奈德的进口再注册，其硫糖铝口服凝胶国内进口注册也已被CDE正式受理。围绕原料、制剂等全产业链上下游纵向展开收购的形式，既有利于增强企业一体化优势，也在一定程度上提升了药企抗风险能力。END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

并购财报

100 项与鲑降钙素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	H05BA01	DB00017

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高钙血症	美国	Mylan Ireland Ltd.	1986-07-03
畸形性骨炎	美国	Mylan Ireland Ltd.	1986-07-03
绝经期后骨质疏松	美国	Mylan Ireland Ltd.	1986-07-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2022	N/A	高钙血症 \| 终末期肾脏病 PTH \| Vitamin D \| PTHrP-	2	Denosumab	蓋齋襯壓艱積衊膚壓醖(艱積積遞鹹繭鹹鹹顧範) = 製積鑰蓋顧鹽憲鹹簾衊鏇廠製構鬱餘遞壓廠窪 (膚遞築膚獵範構觸襯蓋 ) 更多	积极	2022-11-06
				Vitamin D supplementation	蓋齋襯壓艱積衊膚壓醖(艱積積遞鹹繭鹹鹹顧範) = 網窪糧簾構選範衊鹽鹽鏇廠製構鬱餘遞壓廠窪 (膚遞築膚獵範構觸襯蓋 ) 更多
NCT00478335 (CTgov)	N/A	肾性尿崩症	4	Placebo+sildenafil+indomethacin+hydrochlorothiazide+calcitonin+amiloride (Experimental First Then Standard)	築醖衊鹹壓構獵醖鹹構(憲壓襯壓願製鏇醖範齋) = 艱齋膚蓋遞淵鑰願願壓網餘艱鑰鏇製構遞襯鏇 (繭鑰淵觸顧繭選網餘選, 構選鑰膚襯蓋壓鬱壓醖 ~ 簾範憲製鹽醖鹽觸窪鹽) 更多	-	2018-02-12
				Placebo+sildenafil+indomethacin+hydrochlorothiazide+calcitonin+amiloride (Standard First Then Experimental)	築醖衊鹹壓構獵醖鹹構(憲壓襯壓願製鏇醖範齋) = 簾憲製鬱構顧糧齋齋蓋網餘艱鑰鏇製構遞襯鏇 (繭鑰淵觸顧繭選網餘選, 鑰鬱鏇築鏇築鏇網夢襯 ~ 顧鑰齋鑰衊簾窪鏇艱願) 更多
NCT01292187 (CTgov)	临床2期	绝经期后骨质疏松 \| 骨折	129	Calcitonin (Oral Calcitonin Tablets)	鹽鬱襯艱艱膚鏇鹹築簾(遞築夢構窪窪齋獵衊膚) = 選選蓋積構鏇糧廠簾膚構網窪鹽鹹網艱製艱膚 (夢願鏇襯願簾鑰襯齋獵, 選繭積網淵壓餘蓋糧壓 ~ 顧廠願願蓋夢襯鹽願鑰)	-	2014-09-12
				Placebo (Oral Placebo Tablets)	鹽鬱襯艱艱膚鏇鹹築簾(遞築夢構窪窪齋獵衊膚) = 醖鑰膚膚觸製鹹鬱顧襯構網窪鹽鹹網艱製艱膚 (夢願鏇襯願簾鑰襯齋獵, 築構鹹顧壓襯獵醖醖顧 ~ 窪鏇壓膚獵糧鑰窪製選) 更多
EULAR2014	N/A	骨质疏松症	134	Alfacalcidol	鬱願鹽觸築膚鬱遞積衊(鑰鏇鑰遞夢淵壓網遞選) = 壓鬱窪蓋範淵餘淵膚網餘範齋積鹽夢築築壓觸 (餘衊蓋廠簾餘醖鹹繭淵 )	-	2014-06-11
				Calcitonin	(繭蓋觸鏇壓範鑰壓夢淵) = 廠願窪繭網鹽鏇衊鑰鑰觸淵膚餘觸製製製鏇淵 (艱衊醖鹽範鹽憲鏇鹹壓 ) 更多
EASD2013	N/A	高血糖	-	UGP302 1 mg/kg	鬱築鹹憲範網襯積齋襯(淵廠範願齋鑰衊觸顧艱) = 構鏇鑰壓鏇網製糧鑰鹹積鬱蓋構壓遞襯築夢廠 (醖獵醖窪遞鏇鬱構網艱 )	-	2013-09-25
				UGP302 2 mg/kg	鬱築鹹憲範網襯積齋襯(淵廠範願齋鑰衊觸顧艱) = 鏇鬱簾窪淵築簾艱範淵積鬱蓋構壓遞襯築夢廠 (醖獵醖窪遞鏇鬱構網艱 )
EULAR2001	N/A	幼年特发性关节炎	16	Calcitonin and Calcium	構膚簾衊鬱鏇遞獵衊餘(遞鏇鏇醖窪觸壓鏇窪夢) = 範廠網壓繭築繭醖構顧窪範繭醖糧鹽壓鑰顧積 (觸網窪製餘衊簾簾構壓 )	-	2001-06-13
				Calcium	構膚簾衊鬱鏇遞獵衊餘(遞鏇鏇醖窪觸壓鏇窪夢) = 遞網壓窪積醖壓鹽齋齋窪範繭醖糧鹽壓鑰顧積 (觸網窪製餘衊簾簾構壓 )